Goldman Sachs upgraded Cytokinetics (CYTK) to Buy from Neutral with a $95 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Poised for Global Growth with MYQORZO Approval and Anticipated Regulatory Milestones
- Cytokinetics announces MYQORZO approved by China NMPA
- Cytokinetics Receives EU Recommendation for MYQORZO®
- Cytokinetics announces positive CHMP opinion on MYQORZO
- Promising Outlook for Cytokinetics: Buy Rating Supported by Aficamten’s Advantages in HCM Treatment